On “World Cancer Day”, World Health Organization (WHO) has published Global Cancer Report. It states that in recent years, the number of global cancer patients and its death cases are increasing at an alarming speed, and nearly half of newly increased cancer cases occur in Asia, among which, the majority have been found in China. China ranks the first in terms of newly increased cancer cases. Regarding four kinds of malignant tumors like liver cancer, esophagus cancer, stomach cancer and lung cancer, China ranks the first in the world in terms of its new cases and death toll.
Global Distribution of the Highest Cancer Incidence for Males
Huge Population Base Makes Chinese Cancer Death Toll No. 1
Early this year, Chen Wanqing, vice director of National Tumor Registration Center, has published Cancer Statistics in China, 2015 in the magazine of “CA：A Cancer Journal for A Cancer Journal for Clinicians” with others. It shows the latest cancer incidence and death rate as well as other data in China. As Chinese huge population of 1.37 billion accounts for about one fifth of global population, Chinese data has taken up a large part of global cancer load. In other words, about 22% of new cancer cases in the world and 27% of cancer death cases happen in China.
Chinese new cancer cases and death toll are respectively 4,292,000 and 2,814,000 in 2015, which amount to average addition of 12,000 cancer patients and death toll of 7,500 each day. Lung cancer is known as the cancer with highest incidence and death rate, followed by gastric cancer, esophagus cancer and liver cancer. These four kinds of cancer take up 57% in total and account for a quarter of cancer death toll in the world.
Long Approval Process of New Drug Disappoints Patients
In the past few days, some media report that clinical examination takes about 6-10 months, production application takes about 20 months in the fast way and 62 months in the slow way, and it takes a total of 5 years in China for an introduction of a new imported drug. By comparison, it takes averagely 303 days in America and around 1 year in Europe.
“It takes averagely 8 years to approve new drugs in China, while 4 years in other markets”, said Alex Gorsky, CEO of Johnson & Johnson.
Li Lida, CEO of Eli Lilly, said that, “we are now still worried about time lag of drug approval and it takes several years longer in China than other places”.
Tumor Drugs Approved by American FDA from 2014 to 2017 Barely Appear in China
Drugs Approved in 2017
Alunbrig (brigatinib); Ariad Pharmaceuticals; For the treatment of advanced ALK-positive metastatic non-small cell lung cancer, Approved April 2017
Bavencio (avelumab) ; EMD Serono/Pfizer; For the treatment of Merkel cell carcinoma , Approved March 2017
Imfinzi (durvalumab); AstraZeneca; For the treatment of advanced or metastatic urothelial carcinoma, Approved May 2017
Kisqali (ribociclib); Novartis; For the treatment of breast cancer, Approved March 2017
Nerlynx (neratinib); Puma Biotech; For the treatment of HER2 breast cancer, Approved July 2017
Rydapt (midostaurin); Novartis; For the treatment of FLT3 positive acute myeloid leukemia and mastocytosis , Approved April 2017
Xermelo (telotristat ethyl); Lexicon Pharmaceuticals; For the treatment of carcinoid syndrome diarrhea, Approved February 2017
Tesaro; For the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer , Approved March 2017
Drugs Approved in 2016
Cabometyx (cabozantinib); Exelixis; For the treatment of advanced renal cell carcinoma, Approved April 2016
Keytruda (pembrolizumab); Merck; For the treatment of head and neck squamous cell cancer , Approved August 2016
Lartruvo (olaratumab) ; Eli Lilly; For the treatment of soft tissue sarcoma, Approved October 2016
Lenvima (lenvatinib); Eisai; For the treatment of advanced renal cell carcinoma, Approved May 2016
Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of classical Hodgkin lymphoma, Approved May 2016
Rubraca (rucaparib); Clovis Oncology; For the treatment of advanced ovarian cancer in women with deleterious germline or somatic BRCA mutation, Approved December 2016
Sustol (granisetron); Heron Therapeutics; For the prevention of chemotherapy-induced nausea and vomiting, Approved August 2016
Syndros (dronabinol oral solution); Insys Therapeutics; For the treatment of anorexia associated with AIDS and nausea and vomiting associated with cancer chemotherapy, Approved July 2016
Tecentriq (atezolizumab); Genentech; For the treatment of urothelial carcinoma and metastatic non-small cell lung cancer, Approved May 2016
Venclexta (venetoclax); AbbVie; For the treatment of chronic lymphocytic leukemia with 17p deletion, Approved April 2016
Drugs Approved in 2015
Roche; For the treatment of ALK-positive, metastatic non-small cell lung cancer , Approved December 2015
Cotellic (cobimetinib) ; Genentech; For the treatment of BRAF V600E or V600K melanoma, Approved November 2015
Darzalex (daratumumab); Janssen Biotech; For the treatment of multiple myeloma, Approved November 2015
Empliciti (elotuzumab); Bristol-Myers Squibb; For the treatment of patients with multiple myeloma who have received prior therapies, Approved November 2015
Farydak (panobinostat); Novartis; For the treatment of multiple myeloma, Approved February 2015
Ibrance (palbociclib); Pfizer; For the treatment of ER-positive, HER2-negative breast cancer, Approved February 2015
Imlygic (talimogene laherparepvec) ; Amgen; For the treatment of unresectable recurrent melanoma, Approved October 2015
Keytruda (pembrolizumab); Merck; For the treatment of PD-L1 positive advanced non-small cell lung cancer, Approved October 2015
Lenvima (lenvatinib); Eisai; For the treatment of thyroid cancer, Approved February 2015
Lonsurf (trifluridine and tipiracil); Taiho Oncology; For the treatment of metastatic colorectal cancer , Approved September 2015
Ninlaro (ixazomib); Millennium Pharmaceuticals; For the treatment of multiple myeloma, Approved November 2015
Odomzo (sonidegib); Novartis; For the treatment of locally advanced basal cell carcinoma, July 2015
Onivyde (irinotecan liposome injection); Merrimack; For the treatment of metastatic pancreatic cancer following gemcitabine-based therapy, Approved October 2015
Opdivo (nivolumab); Bristol-Myers Squibb; For the treatment of advanced renal cell carcinoma, Approved November 2015
Portrazza (necitumumab) ; Eli Lilly; For the treatment of metastatic squamous non-small cell lung cancer, Approved November 2015
Tagrisso (osimertinib); AstraZeneca; For the treatment of EGFR T790M mutation positive non-small cell lung cancer , Approved November 2015
Unituxin (dinutuximab); United Therapeutics; For the treatment of pediatrics with high-risk neuroblastoma, Approved March 2015
Varubi (rolapitant); Tesaro; For the prevention of delayed nausea and vomiting associated with chemotherapy, Approved September 2015
Vistogard (uridine triacetate); Wellstat Therapeutics; For the emergency treatment of patients with a fluorouracil or capecitabine overdose, Approved December 2015
Yondelis (trabectedin); Janssen; For the treatment of liposarcoma or leiomyosarcoma, Approved October 2015
Drugs Approved in 2014
Akynzeo (netupitant and palonosetron); Helsinn; For the prevention of chemotherapy-induced nausea and vomiting, Approved October 2014
Beleodaq (belinostat); Spectrum Pharmaceuticals; For the treatment of relapsed or refractory peripheral T-cell lymphoma, Approved July 2014
Blincyto (blinatumomab); Amgen; For the treatment of Philadelphia chromosome-negative relapsed /refractory B cell precursor acute lymphoblastic leukemia, Approved December 2014
Cyramza (ramucirumab); Eli Lilly; For the treatment of gastric cancer, Approved April 2014
Imbruvica (ibrutinib); Pharmacyclics; For the treatment of chronic lymphocytic leukemia and Waldenstrom macroglobulinemia, Approved February 2014
Keytruda (pembrolizumab); Merck; For the treatment of unresectable or metastatic melanoma, Approved September 2014
Drug import and export companies in HK have opened green channel for the minority of Chinese cancer patients
As globally renowned free trade port, HK enjoys advanced finance, logistics and trade system. In addition, the latest cancer drugs in the world appear in its market several years earlier than Chinese mainland. As for drugs which have appeared in the market earlier like Herceptin against breast cancer, its price in HK is nearly RMB 10,000 cheaper than that in Chinese mainland. New drugs appear in the HK market nearly as fast as that in Europe and America, together with its relatively low price, so a large number of cancer patients in Chinese mainland have been attracted to seek for drugs in HK. As reported, the majority of cancer drugs in drugstores and drug market in HK have been purchased by people from Chinese mainland. In addition, as shown by drug import and export license from official website anticancerdrugstore.com of drug wholesaler (Ghitai Pharmaceutical Limited) registered by HK government, the latest drug against ovarian cancer Zejula (niraparib) which this license has applied for import, is exactly exported to some patient in Jiangsu Province of Chinese mainland.
Ghitai Pharmaceutical Limited have been dealing in medicines and pharmaceutical products for more than 30 years. We are an authorized wholesaler which has been duly licensed in accordance with the laws of Hong Kong (Licence No.30/2A/2014).
Ghitai Pharmaceutical Limited specialize in the import, export and sale of new medicines and pharmaceutical products for all major chronic diseases including various types of cancer. Besides serving customers in Hong Kong, we also provide high quality service to customers in Mainland China and around the world. We serve a wide range of customers including hospitals, clinics, doctors, pharmacies, individual customers and biotech companies/institutes.
As an established wholesaler of medicines and pharmaceutical products
Reliability: As a fully licensed dealer who is subject to stringent supervision by government departments, we deal in products which meet internationally recognized health and safety standards.
Ghitai Pharmaceutical Limited
Company Name: Ghitai Pharmaceutical Limited
Contact Person: Ms Lee